We found that EC with high HMGA1 expression is resistant to PARP inhibitors, and HMGA1 inhibition combined with PARP inhibitors is effective in treatment, or screening for ESCC patients with low HMGA1 expression may be effective against PARP inhibitors. This evidence concerns the gene PARP1 and esophageal squamous cell carcinoma.